Prospective Hyperthermia Database in Cancer Patients (HT Register)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Hyperthermie Register.
- Who it may be relevant to
- Registry conditions: Hyperthermia, Cancer. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Germany
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Prospektive Hyperthermie-Datenbank Bei Krebspatienten (HTRegister)
Overview
This monocentric study registry records all cancer patients at the Charité which are treated with hyperthermia to examine the therapeutic use of hyperthermia in cancer patients in the general application and to obtain an accurate risk-benefit balance After confinement in this database are the patients prospectively in order to complications, disease status and survival status tracked. Furthermore there is the possibility in the course of this study to an optional take part in translational accompanying research with the aim of prognostic factors for response to hyperthermia treatment.
Detailed description
A total of 1000 patients with various diseases with the indication for hyperthermia in addition to standard oncological therapy (radiation therapy, chemotherapy, radiochemotherapy) will be included in this registry protocol.
Interventions
- Other Hyperthermie Register
* die Höhe der Temperatur im Zielgebiet (42,5 bis 43 °C), * die Dauer der Anwendung und * die simultane Therapie mit Chemo- und/oder Strahlentherapie
Primary outcome measures
- Effectivity [Time frame: Through the study completion, up to 10 years]
- Toxicity [Time frame: Through the study completion, up to 10 years]
Eligibility criteria
Inclusion criteria
- Contrazeption with female patients at the capable of bearing children age
- Written agreement is present (DvH, ICH-GCP)
- Patients, who participate at the same time in a interventional study, can nevertheless in this register study participate if this none Exclusion criterion for the interventional study represents.
- With children must the treatment with one of the GPOH agreed Pattern take place
Exclusion criteria
- Exclusion criteria for the hyperthermia (such as hip prosthesis in the therapeutic area, metal implants/marker, patients with cardiac pacemakers)
- mental disease, what the proper study participation does not allow.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
Germany · 2 centers
- Clinic for Radio - Oncology and Radiotherapy — Berlin
- Clinic for Radio - Oncology and Radiotherapy — Berlin
Identifiers
NCT: NCT05993910 · HTRegister2014